5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits

Xuemei Huang, David E. Nichols

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, NMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalEuropean Journal of Pharmacology
Volume238
Issue number2-3
DOIs
StatePublished - Jul 20 1993

Fingerprint

Amphetamine
Dopamine
N-Methyl-3,4-methylenedioxyamphetamine
Dihydroxyphenylalanine
Serotonin
Serotonin 5-HT2 Receptor Agonists
Serotonin Agents
Corpus Striatum
Paroxetine
Dopamine Receptors
Binding Sites
Injections
3-hydroxybenzylhydrazine
2-aminoindan

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{7cb8820e9bea41fbbee30a976e52afea,
title = "5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits",
abstract = "The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, NMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.",
author = "Xuemei Huang and Nichols, {David E.}",
year = "1993",
month = "7",
day = "20",
doi = "10.1016/0014-2999(93)90859-G",
language = "English (US)",
volume = "238",
pages = "291--296",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. / Huang, Xuemei; Nichols, David E.

In: European Journal of Pharmacology, Vol. 238, No. 2-3, 20.07.1993, p. 291-296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits

AU - Huang, Xuemei

AU - Nichols, David E.

PY - 1993/7/20

Y1 - 1993/7/20

N2 - The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, NMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.

AB - The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, NMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.

UR - http://www.scopus.com/inward/record.url?scp=0027337064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027337064&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(93)90859-G

DO - 10.1016/0014-2999(93)90859-G

M3 - Article

C2 - 8104811

AN - SCOPUS:0027337064

VL - 238

SP - 291

EP - 296

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -